Floatz logo

Thioguanine Anhydrous

B-Cell Adult Acute Lymphocytic Leukemia

Children's Oncology GroupSmall moleculePhase 3Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the B-Cell Adult Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Vincristine Sulfate
SWOG Cancer Research Network
Phase 3BBB
Pegaspargase
National Cancer Institute (NCI)
Phase 3BBB
Dexasone
Mayo Clinic
Phase 3BBB
Cytarabine
Massachusetts General Hospital
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB

View all 50 →

Same molecule, other indications

Thioguanine Anhydrous is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
73 / 100
View asset →
acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
lymphoblastic lymphomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →